Article Abstract

Antithrombotic therapy after transcatheter aortic valve implantation: a new piece of the still unresolved puzzle

Authors: Giuseppe Gargiulo, Marco Valgimigli


The 2017 marks the 40th anniversary of percutaneous coronary intervention (PCI), but also the 15th anniversary for transcatheter aortic valve implantation (TAVI) (1). For more than 50 years, surgical aortic valve replacement (SAVR) has been the standard of care for patients with severe symptomatic aortic stenosis, improving outcomes and prolonging the lives of these patients. In 1990s the transcatheter delivery of a bioprosthetic aortic valve was conceptualized and largely tested in animals.